



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

CLANDRUM@FULBRIGHT.COM
DIRECT DIAL: (512) 536-5674

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

October 22, 2003

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 22, 2003
Date


Charles P. Landrum

MS DD

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/629,329 entitled "METHODS AND COMPOSITIONS USING POLYNUCLEOTIDES AND POLYPEPTIDES OF RANK-ASSOCIATED INHIBITOR (RAIN)" – Bryant G. Darnay*
Our reference: UTSC:761US
Client reference: MDA02-072


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references C1-C16.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:761US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Charles P. Landrum
Patent Agent
Reg. No. 46,855

CPL/kmv
Encl.: as noted

25347280_11.DOC



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Bryant G. Darnay

Serial No.: 10/629,329

Filed: July 29, 2003

For: METHODS AND COMPOSITIONS
USING POLYNUCLEOTIDES AND
POLYPEPTIDES OF RANK-
ASSOCIATED INHIBITOR (RAIN)

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UTSC:761US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 22, 2003

Date

Charles P. Landrum
Charles P. Landrum

INFORMATION DISCLOSURE STATEMENT

MS DD

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:761US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Charles P. Landrum
Reg. No. 46,855
Agent for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: October 22, 2003

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSC:761US

Serial N .

10/629,329

Applicant

Bryant G. Darnay

Filing Date:

July 29, 2003

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|----------------|--------------|---|
| | C11 | Li <i>et al.</i> , "RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism," <i>Proc. Natl. Acad. Sci., USA</i> , 97(4):1566-1571, 2000. |
| | C12 | Mizuno <i>et al.</i> , "Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin," <i>Biochem. Biophys. Res. Commun.</i> , 247:610-615, 1998. |
| | C13 | Okahashi <i>et al.</i> , "Osteoclast differentiation is associated with transient upregulation of cyclin-dependent kinase inhibitors p21WAF1/CIP1 and p27KIP1," <i>J. Cell Biochem.</i> , 80(3):339-345, 2001. |
| | C14 | Pullen <i>et al.</i> , "CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs)," <i>J. Biol.Chem.</i> , 274:14246-14254, 1999. |
| | C15 | Scheven <i>et al.</i> , "In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population," <i>Nature</i> , 321:79-81, 1986. |
| | C16 | Takayanagi <i>et al.</i> , "Induction and activation of the transcription factor NFATc1 (NAFT2) integrate RANKL signaling in terminal differentiation of osteoclast," <i>Dev. Cell</i> , 3(6):889-901, 2002. |

25336774.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)